(NASDAQ: NXTC) Nextcure's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Nextcure's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NXTC's revenue for 2028 to be $296,870,850, with the lowest NXTC revenue forecast at $296,870,850, and the highest NXTC revenue forecast at $296,870,850. On average, 1 Wall Street analysts forecast NXTC's revenue for 2029 to be $646,954,400, with the lowest NXTC revenue forecast at $646,954,400, and the highest NXTC revenue forecast at $646,954,400.
In 2030, NXTC is forecast to generate $1,134,270,702 in revenue, with the lowest revenue forecast at $1,134,270,702 and the highest revenue forecast at $1,134,270,702.